Personalized oncolytic vaccines for cancer immunotherapy

Project Information

PeptiCrad

Grant agreement ID: 681219

DOI

10.3030/681219

Project closed

EC signature date 6 June 2016

Start date 1 July 2016

End date 30 June 2022

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 1 975 705,00

EU contribution

€ 1 975 705,00

Coordinated by

HELSINGIN YLIOPISTO
Finland

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (27)

Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

Author(s): Erkko Ylösmäki, Leena Ylösmäki, Manlio Fusciello, Beatriz Martins, Petra Ahokas, Hanne Cojoc, Arttu Uoti, Sara Feola, Anna Kreutzman, Tuuli Ranki, Julia Karbach, Tapani Viitala, Petri Priha, Elke Jäger, Sari Pesonen, Vincenzo Cerullo
Published in: Molecular Therapy - Oncolytics, Issue 20, 2021, Page(s) 459-469, ISSN 2372-7705
Publisher: Cell Press
DOI: 10.1016/j.omto.2021.02.006

Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma

Author(s): Jacopo Chiaro, Henna H.E. Kasanen, Thomas Whalley, Cristian Capasso, Mikaela Grönholm, Sara Feola, Karita Peltonen, Firas Hamdan, Micaela Hernberg, Siru Mäkelä, Hanna Karhapää, Paul E. Brown, Beatriz Martins, Manlio Fusciello, Erkko O. Ylösmäki, Dario Greco, Anna S. Kreutzman, Satu Mustjoki, Barbara Szomolay, Vincenzo Cerullo
Published in: Cancer Immunology Research, Issue 9/8, 2021, Page(s) 981-993, ISSN 2326-6066
Publisher: American Association for Cancer Research Inc.
DOI: 10.1158/2326-6066.cir-20-0814

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

Author(s): Firas Hamdan, Erkko Ylösmäki, Jacopo Chiaro, Yvonne Giannoula, Maeve Long, Manlio Fusciello, Sara Feola, Beatriz Martins, Michaela Feodoroff, Gabriella Antignani, Salvatore Russo, Otto Kari, Moon Hee Lee, Petrus Järvinen, Harry Nisen, Anna Kreutzman, Jeanette Leusen, Satu Mustjoki, Thomas G McWilliams, Mikaela Grönholm, Vincenzo Cerullo
Published in: Journal for ImmunoTherapy of Cancer, Issue 9/8, 2021, Page(s) e003000, ISSN 2051-1426
Publisher: BMJ journal
DOI: 10.1136/jitc-2021-003000

Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy

Author(s): Karita Peltonen, Sara Feola, Husen M. Umer, Jacopo Chiaro, Georgios Mermelekas, Erkko Ylösmäki, Sari Pesonen, Rui M. M. Branca, Janne Lehtiö, Vincenzo Cerullo
Published in: Cancers, Issue 13/14, 2021, Page(s) 3408, ISSN 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers13143408

PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification

Author(s): Sara Feola, Markus Haapala, Karita Peltonen, Cristian Capasso, Beatriz Martins, Gabriella Antignani, Antonio Federico, Vilja Pietiäinen, Jacopo Chiaro, Michaela Feodoroff, Salvatore Russo, Antti Rannikko, Manlio Fusciello, Satu Koskela, Jukka Partanen, Firas Hamdan, Sari M. Tähkä, Erkko Ylösmäki, Dario Greco, Mikaela Grönholm, Tuija Kekarainen, Masoumeh Eshaghi, Olga L. Gurvich, Seppo Ylä-H
Published in: ACS Nano, Issue 15, 2021, Page(s) 15992-16010, ISSN 1936-0851
Publisher: American Chemical Society
DOI: 10.1021/acsnano.1c04371

GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses

Author(s): Firas Hamdan, Beatriz Martins, Michaela Feodoroff, Yvonne Giannoula, Sara Feola, Manlio Fusciello, Jacopo Chiaro, Gabriella Antignani, Mikaela Grönholm, Erkko Ylösmäki, Vincenzo Cerullo
Published in: Molecular Therapy - Methods & Clinical Development, Issue 20, 2021, Page(s) 625-634, ISSN 2329-0501
Publisher: Cell Press
DOI: 10.1016/j.omtm.2021.01.014

Patient-Derived Organoids for Precision Cancer Immunotherapy

Author(s): Mikaela Grönholm, Michaela Feodoroff, Gabriella Antignani, Beatriz Martins, Firas Hamdan, Vincenzo Cerullo
Published in: Cancer Research, Issue 81/12, 2021, Page(s) 3149-3155, ISSN 0008-5472
Publisher: American Association for Cancer Research
DOI: 10.1158/0008-5472.can-20-4026

Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity.

Author(s): Hirvinen M, Capasso C, Guse K, Garofalo M, Vitale A, Ahonen M, Kuryk L, Vähä-Koskela M, Hemminki A, Fortino V, Greco D, Cerullo V.
Published in: Molecular Therapy oncolytics, Issue 23, 2016, Page(s) 3-16002, ISSN 2372-7705
Publisher: Cell Press
DOI: 10.1038/mto.2016.2

Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy

Author(s): Leena Ylösmäki, Beatrice Polini, Sara Carpi, Beatriz Martins, Elena Smertina, Sara Feola, Manlio Fusciello, Karita Peltonen, Paola Nieri, Erkko Ylösmäki, Vincenzo Cerullo
Published in: PLOS ONE, Issue 14/10, 2019, Page(s) e0224072, ISSN 1932-6203
Publisher: Public Library of Science
DOI: 10.1371/journal.pone.0224072

A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines

Author(s): Feola S, Chiaro J, Martins B, Russo S, Fusciello M, Ylösmäki E, Bonini C, Ruggiero E, Hamdan F, Feodoroff M, Antignani G, Viitala T, Pesonen S, Grönholm M, Branca RMM, Lehtiö J, Cerullo V.
Published in: eLIFE, Issue 2022 Mar 22;11, 2022, Page(s) e71156, ISSN 2050-084X
Publisher: eLife Sciences Publications
DOI: 10.7554/elife.71156

Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment

Author(s): Feola S., Russo S., Ylösmäki E., Cerullo V.
Published in: Pharmacology & Therapeutics, Issue 236, 2022, Page(s) 108103, ISSN 2468-1016
Publisher: Elsevier - Sciencedirect
DOI: 10.1016/j.pharmthera.2021.108103

Novel personalized cancer vaccine platform based on Bacillus Calmette-Guèrin

Author(s): Erkko Ylösmäki, Manlio Fusciello, Beatriz Martins, Sara Feola, Firas Hamdan, Jacopo Chiaro, Leena Ylösmäki, Matthew J Vaughan, Tapani Viitala, Prasad S Kulkarni, Vincenzo Cerullo
Published in: Journal for ImmunoTherapy of Cancer, Issue 9/7, 2021, Page(s) e002707, ISSN 2051-1426
Publisher: BMJ Journals
DOI: 10.1136/jitc-2021-002707

Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity

Author(s): Garofalo M, Iovine B, Kuryk L, Capasso C, Hirvinen M, Vitale A, Yliperttula M, Bevilacqua MA, Cerullo V.
Published in: Molecular Cancer Therapeutics, Issue 15(4), 2016, Page(s) 651-660, ISSN 1535-7163
Publisher: American Association for Cancer Research
DOI: 10.1158/1535-7163.mct-15-0559

Pathogens: Our Allies against Cancer?

Author(s): Buonaguro L, Cerullo V.
Published in: Molecular Therapy, Issue Jan 6; 29(1), 2021, Page(s) 10-12, ISSN 1525-0016
Publisher: Nature Publishing Group
DOI: 10.1016/j.ymthe.2020.12.005

β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection

Author(s): Guenther C, Faisal I, Fusciello M, Sokolova M, Harjunpää H, Ilander M, Tallberg R, Vartiainen MK, Alon R, Gonzalez-Granado JM, Cerullo V, Fagerholm SC.
Published in: Cancer Immunology Research, Issue 9(11), 2021, Page(s) 1354-1369, ISSN 2326-6074
Publisher: AACR Journals
DOI: 10.1158/2326-6066.cir-21-0094

A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella

Author(s): Fusciello M, Ylösmäki E, Feola S, Uoti A, Martins B, Aalto K, Hamdan F, Chiaro J, Russo S, Viitala T, Cerullo V.
Published in: Molecular Therapy Oncolytics, Issue 2022 Apr 19;25, 2022, Page(s) 137-145, ISSN 2372-7705
Publisher: Cell Press - Elsevier
DOI: 10.1016/j.omto.2022.04.002

A novel in silico framework to improve MHC-I epitopes and break the tolerance to melanoma

Author(s): Cristian Capasso, Aniket Magarkar, Victor Cervera-Carrascon, Manlio Fusciello, Sara Feola, Martin Muller, Mariangela Garofalo, Lukasz Kuryk, Siri Tähtinen, Lucio Pastore, Alex Bunker, Vincenzo Cerullo
Published in: OncoImmunology, Issue 6/9, 2017, Page(s) e1319028, ISSN 2162-402X
Publisher: Taylor & Francis
DOI: 10.1080/2162402X.2017.1319028

Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses

Author(s): Erkko Ylösmäki, Cristina Malorzo, Cristian Capasso, Oona Honkasalo, Manlio Fusciello, Beatriz Martins, Leena Ylösmäki, Antti Louna, Sara Feola, Henrik Paavilainen, Karita Peltonen, Veijo Hukkanen, Tapani Viitala, Vincenzo Cerullo
Published in: Molecular Therapy, Issue 26/9, 2018, Page(s) 2315-2325, ISSN 1525-0016
Publisher: Nature Publishing Group
DOI: 10.1016/j.ymthe.2018.06.008

Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors

Author(s): S. Feola, C. Capasso, M. Fusciello, B. Martins, S. Tähtinen, M. Medeot, S. Carpi, F. Frascaro, E. Ylosmäki, K. Peltonen, L. Pastore, V. Cerullo
Published in: OncoImmunology, 2018, Page(s) e1457596, ISSN 2162-402X
Publisher: Taylor & Francis
DOI: 10.1080/2162402x.2018.1457596

Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma

Author(s): Cristian Capasso, Mari Hirvinen, Mariangela Garofalo, Dmitrii Romaniuk, Lukasz Kuryk, Teea Sarvela, Andrea Vitale, Maxim Antopolsky, Aniket Magarkar, Tapani Viitala, Teemu Suutari, Alex Bunker, Marjo Yliperttula, Arto Urtti, Vincenzo Cerullo
Published in: OncoImmunology, Issue 5/4, 2015, Page(s) e1105429, ISSN 2162-402X
Publisher: Taylor & Francis online
DOI: 10.1080/2162402X.2015.1105429

Artificially cloaked viral nanovaccine for cancer immunotherapy

Author(s): Manlio Fusciello, Flavia Fontana, Siri Tähtinen, Cristian Capasso, Sara Feola, Beatriz Martins, Jacopo Chiaro, Karita Peltonen, Leena Ylösmäki, Erkko Ylösmäki, Firas Hamdan, Otto K. Kari, Joseph Ndika, Harri Alenius, Arto Urtti, Jouni T. Hirvonen, Hélder A. Santos, Vincenzo Cerullo
Published in: Nature Communications, Issue 10/1, 2019, ISSN 2041-1723
Publisher: Nature Publishing Group
DOI: 10.1038/s41467-019-13744-8

Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site

Author(s): Alessandra Lopes, Sara Feola, Sophie Ligot, Manlio Fusciello, Gaëlle Vandermeulen, Véronique Préat, Vincenzo Cerullo
Published in: Journal for ImmunoTherapy of Cancer, Issue 7/1, 2019, ISSN 2051-1426
Publisher: BMC part of Spring Nature
DOI: 10.1186/s40425-019-0644-7

Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor

Author(s): Flavia Fontana, Manlio Fusciello, Christianne Groeneveldt, Cristian Capasso, Jacopo Chiaro, Sara Feola, Zehua Liu, Ermei M. Mäkilä, Jarno J. Salonen, Jouni T. Hirvonen, Vincenzo Cerullo, Hélder A. Santos
Published in: ACS Nano, Issue 13/6, 2019, Page(s) 6477-6490, ISSN 1936-0851
Publisher: American Chemical Society
DOI: 10.1021/acsnano.8b09613

Exploiting pre-existing immunity to enhance oncolytic cancer immunotherapy

Author(s): Siri Tähtinen, Sara Feola, Cristian Capasso, Netta Laustio, Christianne Groeneveldt, Erkko O Ylösmäki, Leena Ylösmäki, Beatriz Martins, Manlio Fusciello, Marta Medeot, Maria Tagliamonte, Jacopo Chiaro, Firas Hamdan, Karita Peltonen, Tuuli Ranki, Luigi Buonaguro, Vincenzo Cerullo
Published in: Cancer Research, 2020, Page(s) canres.2062.2019, ISSN 0008-5472
Publisher: American Association for Cancer Research
DOI: 10.1158/0008-5472.can-19-2062

Design and application of oncolytic viruses for cancer immunotherapy

Author(s): Erkko Ylösmäki, Vincenzo Cerullo
Published in: Current Opinion in Biotechnology, Issue 65, 2020, Page(s) 25-36, ISSN 0958-1669
Publisher: Elsevier BV
DOI: 10.1016/j.copbio.2019.11.016

Circulating microRNAs as biomarkers for early diagnosis of cutaneous melanoma

Author(s): Sara Carpi, Beatrice Polini, Stefano Fogli, Adriano Podestà, Erkko Ylösmäki, Vincenzo Cerullo, Antonella Romanini, Paola Nieri
Published in: Expert Review of Molecular Diagnostics, Issue 20/1, 2020, Page(s) 19-30, ISSN 1473-7159
Publisher: Future Drugs Ltd.
DOI: 10.1080/14737159.2020.1696194

Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine

Author(s): Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Fluhler V, De Giorgi C, Fusciello M, Pesonen S, Ylösmäki E, Antignani G, Chiaro J, Hamdan F, Feodoroff M, Grönholm M, Cerullo V.
Published in: Frontiers Immunology, Issue 14 April 2022; 13, 2022, Page(s) 826164, ISSN 1664-3224
Publisher: Frontiers
DOI: 10.3389/fimmu.2022.826164

Non-peer reviewed articles (1)

Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process

Author(s): Sara Feola, Jacopo Chiaro, Beatriz Martins, Vincenzo Cerullo
Published in: Cancers, Issue 12/6, 2020, Page(s) 1660, ISSN 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers12061660

Intellectual Property Rights

Patent (2)

COATED ONCOLYTIC ADENOVIRUSES FOR CANCER VACCINES

Application/Publication number: EP 15723503
Date: 2015-05-18
Applicant(s): HELSINGIN YLIOPISTO

NON-GENETIC MODIFICATION OF ENVELOPED VIRUSES

Application/Publication number: 20 17072366
Date: 2017-09-06
Applicant(s): HELSINGIN YLIOPISTO